Abstract
In the Phase 3 SINUS-24/-52 studies (NCT02912468/NCT02898454) dupilumab significantly reduced requirement for systemic corticosteroids (SCS) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with coexisting asthma typically have poorer outcomes and refractory disease. We report a post hoc analysis of SCS use and asthma outcomes in SINUS-24/52 patients with coexisting asthma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
